GT Biopharma (GTBP) Expected to Announce Quarterly Earnings on Friday

GT Biopharma (NASDAQ:GTBP) will likely be announcing its Q4 2025 results before the market opens on Friday, February 20th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 13, 2026 at 4:00 PM ET.

GT Biopharma (NASDAQ:GTBP) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.45). On average, analysts expect GT Biopharma to post $-7 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

GT Biopharma Trading Down 0.1%

Shares of NASDAQ:GTBP opened at $0.47 on Friday. The company has a market capitalization of $5.01 million, a PE ratio of -0.14 and a beta of 1.21. GT Biopharma has a 12-month low of $0.40 and a 12-month high of $3.85. The business has a 50 day moving average of $0.69 and a two-hundred day moving average of $0.86.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e)” rating on shares of GT Biopharma in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, GT Biopharma currently has an average rating of “Sell”.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).